Alpha-conotoxins act on postsynaptic membranes, they bind to the nicotinic acetylcholine receptors (nAChR) and thus inhibit them. This toxin blocks alpha-3-beta-2/CHRNA3-CHRNB2 nAChR with high selectivity (IC(50)=8.67 nM (on rat) and 17.5 (on human)) (PubMed:24398291). Has also weaker activity on alpha-6/alpha-3-beta-2-beta-3 (CHRNA6/CHRNA3-CHRNB2-CHRNB3) (IC(50)=108 nM (on rat)), alpha-6/alpha-3-beta-4 (CHRNA6/CHRNA3-CHRNB4) (IC(50)=121 nM (on rat)), alpha-3-beta-4 (CHRNA3-CHRNB4) (IC(50)=148 nM (on rat)), and alpha-7/CHRNA7 nAChRs (IC(50)=3000 nM (on rat)) (PubMed:24398291). When tested on mouse with hot-plate tests, this toxin significantly increases the base pain threshold and shows analgesic effects (PubMed:26742048). Expressed by the venom duct. The cysteine framework is I (CC-C-C). Alpha4/7 pattern. Does not block alpha-9-alpha-10/CHRNA9-CHRNA10, alpha-2-beta-2/CHRNA2-CHRNB2, alpha-2-beta-4/CHRNA2-CHRNB4, alpha-3-beta-4/CHRNA3-CHRNB4, alpha-4-beta-2/CHRNA4-CHRNB2, alpha-4-beta-4/CHRNA4-CHRNB4, alpha-6/alpha-3-beta-2-beta-3 (CHRNA6/CHRNA3-CHRNB2-CHRNB3), alpha-6-beta-4/CHRNA6-CHRNB4, and alpha-1-beta-1-epsilon-delta/CHRNA1-CHRNB1-CHRNE-CHRND. Belongs to the conotoxin A superfamily.